FDA Approves Admelog (insulin lispro) Short-Acting " Follow-On " Insulin Product to Treat Diabetes
December 11, 2017 -- The U.S. Food and Drug Administration today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Diabetes | Drugs & Pharmacology | Endocrinology | Food and Drug Administration (FDA) | Humalog | Insulin | Pediatrics | Sugar